Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 31 - 40 of 78

Selected Filters:
7 July 2022

Good Distribution Practices (WHO, 2010)

This document lays down guidelines for the distribution of pharmaceutical products. The guidelines cover products for which a prescription is required by the patient, products which may be provided to a patient without a prescription, biologicals and vaccines.

Supply Chain Management

Document
7 July 2022

Guidance for Providing Informed-choice Counseling on Sexual Health for Women Interested in Pre-exposure Prophylaxis

This guidance for healthcare providers can help promote informed decision making on sexual health for women who have expressed interest in using PrEP as part of their HIV risk-reduction strategy.

Service Delivery

External Link
7 July 2022

Tools and resources for building and implementing strategic communications and branding

PrEP uptake requires careful planning along with marketing and communications strategies. Evidence-informed marketing and communications strategies can ensure vital activities are planned to not only introduce and scale up PrEP use but to also make sure PrEP is understood and used in ways that have an impact on people’s health and health seeking behaviors. Check…

Demand Creation/Marketing

External Link
7 July 2022

Social Behavior Change Communication (SBCC) Toolkit

C-Change’s Capacity Strengthening Toolkit for Social Behaviour Change Communication (SBCC) comprises tools, products, online resources, and courses and training in SBCC. Each component can be used alone or in concert with the other resources.

Demand Creation/Marketing

External Link
7 July 2022

Social & Behavior Change Communication Implementation Kits

This website features multiple social and behavior change communication implementation kits.

Demand Creation/Marketing

External Link
7 July 2022

Provider Behavior Change Implementation Kit

This I-Kit provides step-by-step guidance on using social behavior change communication to change provider behavior, and thereby improve client outcomes. The I-Kit is designed to help the reader understand factors that influence provider behavior, design an assessment to understand the specific barriers providers face, and develop an SBCC intervention to address those barriers.

Demand Creation/Marketing, Service Delivery

External Link
7 July 2022

The Power of Demand Generation

Demand generation increases awareness of and demand for health products or services among a particular intended audience through social and behavior change communication and social marketing techniques. This learning module outlines the key concepts and definitions of demand generation.

Demand Creation/Marketing

External Link
7 July 2022

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

This study compares the effectiveness and cost-effectiveness of providing antiretroviral therapy vs PrEP in South Africa

Financing & Costing

External Link
7 July 2022

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

This study estimates the cost-effectiveness of daily oral PrEP, with a protective effect against the herpes simplex virus as well as HIV, among HIV serodifferent couples in South Africa

Financing & Costing

External Link
7 July 2022

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

External Link